Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Savulescu Camelia, Ganser Iris, Nicolay Nathalie, Lajot Adrien, Campos Sandra, Martínez-Baz Iván, Rodrigues Ana Paula, Vandromme Mathil, Cara-Rodríguez Marta, Echeverría Aitziber, Gaio Vânia, Parsy Marie-Pierre, Roldan Garrido Ana, Castilla Jesús, Guiomar Raquel, Bacci Sabrina, Rose Angela Mc, VEBIS hospital network RSV IE group
Аннотация
We measured effectiveness of nirsevimab against laboratory-confirmed respiratory syncytial virus (RSV) infection in a test-negative case-control study among children aged < 24 months hospitalised for severe acute respiratory infection in three European countries. The overall effectiveness in the 2024/25 season among 2,201 children was 79% (95% CI: 58 to 89) and 85%, 78% and 69% at < 30, 30-89 and 90-215 days since immunisation. Immunisation was effective for preventing RSV-related hospitalisation in children, but effectiveness by time since immunisation needs monitoring in future seasons.
Предметные рубрики MeSH
HumansRespiratory Syncytial Virus InfectionsInfantPilot ProjectsHospitalizationMaleFemaleEuropeCase-Control StudiesRespiratory Syncytial Virus, HumanRespiratory Tract InfectionsAntibodies, Monoclonal, HumanizedChild, PreschoolAntiviral AgentsTreatment OutcomeRespiratory Syncytial VirusesSeasonsAcute DiseasePalivizumab